Research programme: cancer and infectious disease therapeutics - Caliber Biotherapeutics

Drug Profile

Research programme: cancer and infectious disease therapeutics - Caliber Biotherapeutics

Alternative Names: Infectious disease vaccines - Caliber Biotherapeutics; Pandemic influenza vaccine - Caliber Biotherapeutics/DARPA; Plant-made pharmaceuticals (PMP) based biobetter mAb candidates - Caliber Biotherapeutics; Rituxan biobetter candidate for cancer - Caliber Biotherapeutics; Rituximab biobetter candidates - Caliber Biotherapeutics

Latest Information Update: 13 Jun 2013

Price : $50

At a glance

  • Originator Caliber Biotherapeutics
  • Developer Caliber Biotherapeutics; Defense Advanced Research Projects Agency
  • Class Influenza A vaccines; Monoclonal antibodies; Vaccines
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Influenza A virus infections

Most Recent Events

  • 13 Jun 2013 Early research for Cancer is ongoing in USA
  • 13 Jun 2013 Early research in Influenza A virus infections (prevention) in USA (Parenteral)
  • 27 Apr 2011 Cancer and infectious disease therapeutics (Caliber Biotherapeutics) are available for licensing as of 25 Apr 2011. http://www.caliberbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top